The NAi platform is in a class of its own – its differentiated ability to generate new knowledge from real patients unlocks previously hidden cause and effect relationships. A causal map generated by the platform identified mitochondrial dysregulation as the cause of many disparate diseases in oncology, wound healing, aging.

In the cell, mitochondria play an essential role in generating energy. Dysregulation of mitochondrial metabolism can cause energy deficits and damage to cellular components. BPM31510, a nanostructure delivering CoQ10, acts at the source of these conditions to rebalance mitochondrial metabolism.

Interestingly, in the unique metabolic environment of the tumor, this triggers cancer cell death.

With these insights from the NAi platform, BPGbio expanded its original topical form of BPM31510 into an IV formulation and an oral formulation for a suite of clinical trials in mitochondrial medicine:

Topical BPM31510: Completed a Phase 1 trial for Epidermolysis Bullosa, and Phase 2 for Squamous Cell Carcinoma;

BPM31510IV: Currently in phase 2b for Glioblastoma and phase 2a for Pancreatic cancer (Ph2) and exploring phase 3 in Primary Q10 Deficiency (Ph2);

BPM31510 Oral: Completed a phase 1 trial in sarcopenia.